LOS ANGELES–(BUSINESS WIRE)—- $CDXC #ChromaDex–ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2024. First Quarter 2024 Financial and Recent Operational Highlights Total net sales were $22.2 million, with $17.4 million from Tru Niagen®. Solid gross margin of 60.7%, an increase of 80 basis points, compared to…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
